N-acetylcysteine improves residual renal function in peritoneal dialysis patients: A pilot study

Peritoneal Dialysis International

Volumn 31, Issue 5, 2011, Pages 545-550

  Feldman, Leonid ^a,b   Shani, Michal ^b,c   Efrati, Shai ^a,b   Beberashvili, Ilia ^a   Yakov Hai, Iris ^a   Abramov, Elena ^a   Sinuani, Inna ^a,b   Rosenberg, Roza ^a   Weissgarten, Joshua ^a,b  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c CLALIT HEALTH SERVICES   (Israel)

Author keywords

N Acetylcysteine; Residual renal function

Indexed keywords

ACETYLCYSTEINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; MALE; PERITONEAL DIALYSIS; PILOT STUDY; PRIORITY JOURNAL; TREATMENT DURATION; URINE VOLUME;

ACETYLCYSTEINE; AGED; CREATININE; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PERITONEAL DIALYSIS; PILOT PROJECTS; PROSPECTIVE STUDIES; URINE;

EID: 84856155519     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2009.00263     Document Type: Article

References (26)

1. Termorshuizen F, Korevaar J, Dekker F, van Manen J, Boeschoten E, Krediet R; NECOSAD Study Group. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol 2003; 14:2851-60.
2. Wang A. The "heart" of peritoneal dialysis. Perit Dial Int 2007; 27(Suppl 2):S228-32.
3. Bargman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12:2158-62.
4. Clerbaux G, Francart J, Wallemacq P, Robert A, Goffin E. Evaluation of peritoneal transport properties at onset of peritoneal dialysis and longitudinal follow-up. Nephrol Dial Transplant 2006; 21:1032-9.
5. Konings C, Kooman J, Schonck M, Dammers R, Cheriex E, Palmans Meulemans A, et al. Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int 2002; 22:477-87.
6. Churchill D, Thorpe K, Nolph K, Keshaviah P, Oreopoulos D, Page D. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1998; 9:1285-92.
7. Termorshuizen F, Korevaar J, Dekker F, van Manen J, Boeschoten E, Krediet R; NECOSAD Study Group. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003; 41:1293-302.
8. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307-20.
9. Chung S, Heimburger O, Stenvinkel P, Qureshi A, Lindholm B. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 2003; 18:590-7.
10. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107:992-5.
11. Feldman L, Efrati S, Eviatar E, Abramsohn R, Yarovoy I, Gersch E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int 2007; 72:359-63.
12. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343:180-4.
13. Heyman S, Goldfarb M, Shina A, Karmeli F, Rosen S. N-Acetylcysteine ameliorates renal microcirculation: studies in rats. Kidney Int 2003; 63:634-41.
14. Efrati S, Berman S, Ilgiyeav I, Siman-Tov Y, Averbukh Z, Weissgarten J. Differential effects of N-acetylcysteine, theophylline or bicarbonate on contrast-induced rat renal vasoconstriction. Am J Nephrol 2009; 29:181-91.
15. Pride E, Gustafson J, Graham A, Spainhour L, Mauck V, Brown P, et al. Comparison of a 2.5% and a 4.25% dextrose peritoneal equilibration test. Perit Dial Int 2002; 22:365-70.
16. Peritoneal Dialysis Adequacy 2006 Work Group. Clinical practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis 2006; 48(Suppl 1):S98-129.
17. Prescott L, Illingworth R, Critchey J, Stewart M, Adam R, Proudfoot A. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. BMJ 1979; 2:1097-100.
18. Mazzon E, Britti D, De Sarro A, Caputi A, Currocrea S. Effect of N-acetylcysteine on gentamicin-mediated nephropathy in rats. Eur J Pharmacol 2001; 424:75-83.
19. Feldman L, Efrati S, Dishy V, Katchko L, Berman S, Averbukh M, et al. N-Acetylcysteine ameliorates amphotericin-induced nephropathy in rats. Nephron Physiol 2005; 99:23-7.
20. Freire Cerqueira N, Hussni C, Bonetti Yoshida W, Lopes Sequeira J, Padovani C. Effects of pentoxifylline and n-acetylcysteine on injuries caused by ischemia and re-perfusion of splanchnic organs in rats. Int Angiol 2008; 27:512-21.
21. Locatelli F, Canaud B, Eckardt K, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18:1272-80.
22. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:154-60.
23. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356:1213-18.
24. Izzedine H, Guerin V, Launay-Vacher V, Bernard M, Deray G. Effect of N-acetylcysteine on serum creatinine level. Nephrol Dial Transplant 2001; 16:1514-15.
25. Hoffman U, Fischereder M, Kruger B, Drobnik W, Kramer B. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15:407-10.
26. Rehman T, Fought J, Solomon R. N-Acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients. Clin J Am Soc Nephrol 2008; 3:1610-14.